Singapore markets closed

CEL-SCI Corporation (CVM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
12.16+0.86 (+7.61%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.30
Open11.38
Bid12.00 x 900
Ask12.16 x 900
Day's range11.09 - 12.25
52-week range7.08 - 40.91
Volume2,394,164
Avg. volume1,950,773
Market cap523.223M
Beta (5Y monthly)2.24
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Aug 1996
1y target estN/A
  • Motley Fool

    Why CEL-SCI Stock Soared Today

    The company attempted to clarify "confusion" related to its recent late-stage clinical results.

  • Motley Fool

    3 Biotechs to Avoid Like the Plague in July

    Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study.

  • Motley Fool

    Will All End Well for This Popular Reddit Biotech?

    On June 28, shares of Cel-Sci (NYSEMKT: CVM) plunged nearly 70% peak-to-trough before recovering. The reason behind the wild price action couldn't be more obvious -- the company's pivotal phase 3 study involving its Multikine immunotherapy did not meet its primary endpoint of improving the overall survival (OS) of head and neck cancer patients. Cel-Sci had been extremely popular among traders of the r/WallStreetBets community due to its short interest -- standing as high as 24% before the data release.